title: Primary cutaneous B-cell lymphoma.
abstract: Primary cutaneous B-cell lymphomas include extranodal marginal zone B-cell lymphoma, follicular lymphoma, large B-cell lymphoma, and, rarely, mantle cell lymphoma. Our purpose in conducting this review was to determine the clinical and behavioral characteristics of primary cutaneous B-cell lymphomas, their relationship to infectious triggers, and therapeutic response. We conducted a retrospective chart review of 23 adult patients presenting to the dermatology clinic at M. D. Anderson Cancer Center with primary cutaneous B-cell lymphoma between January 1999 and May 2003. Primary cutaneous B-cell lymphomas generally present on the head and neck, with the trunk and extremities afflicted to a lesser extent. Patients were found to have serologic evidence of prior infection with Borrelia burgdorferi (n = 10), Helicobacter pylori (n = 5), and Epstein-Barr virus (n = 6). Overall, treatment of primary cutaneous B-cell lymphoma should involve multiple modalities; however, specific treatment aimed at concurrent or suspected infection, particularly B burgdorferi, is a helpful adjunct and may achieve complete remission in a small subset of patients.
authors.affiliation: Department of Dermatology, University of Texas and M. D. Anderson Cancer Center, Houston, Texas 77030, USA. mabogle@hotmail.com
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Bogle
authors.forename: Christy C
authors.initials: CC
authors.lastname: Riddle
authors.forename: Emily M
authors.initials: EM
authors.lastname: Triana
authors.forename: Dan
authors.initials: D
authors.lastname: Jones
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D025065:Borrelia burgdorferi; D015897:Comorbidity; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000453:epidemiology; D005260:Female; D017573:Focal Epithelial Hyperplasia; D016481:Helicobacter Infections / Q000453:epidemiology; D016480:Helicobacter pylori; D006801:Humans; D007150:Immunohistochemistry; D008193:Lyme Disease / Q000453:epidemiology; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism; D008224:Lymphoma, Follicular; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000175:diagnosis / Q000178:diet therapy / Q000453:epidemiology / Q000378:metabolism; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone